OCD medications explained: SSRIs, clomipramine, augmentation, and what to expect

Medication is a first line treatment for OCD alongside ERP. Roughly 40 to 60 percent of patients who complete an adequate medication trial show meaningful symptom reduction, and the combination of medication and ERP outperforms either alone for moderate to severe OCD. This article covers what to expect from OCD medications in plain language.

First line: SSRIs

Selective serotonin reuptake inhibitors are the first line medication class for OCD. The FDA approved options are fluoxetine, fluvoxamine, sertraline, and paroxetine. Escitalopram is used off label and is well studied. All are considered roughly equivalent in efficacy, so choice is driven by side effect profile and prior response.

OCD dosing is higher than depression dosing. Typical target doses are sertraline 200 to 300 mg, fluoxetine 60 to 80 mg, and fluvoxamine 200 to 300 mg. Reaching the target dose is essential. Many patients stall at a subtherapeutic dose and conclude the medication does not work.

Timeline of response

SSRIs for OCD take longer to work than for depression. Initial improvement typically appears at 4 to 6 weeks, and full response can take 10 to 12 weeks at the target dose. An adequate trial is defined as 10 to 12 weeks at the maximum tolerated dose. Switching before completing an adequate trial is common and premature.

Common side effects

Sexual side effects, sleep changes, gastrointestinal upset, and initial anxiety spike are the most common. Most side effects diminish over 2 to 4 weeks. Sexual side effects often persist and are the most common reason for discontinuation. A psychiatrist experienced with OCD can offer strategies to manage this.

Second line: clomipramine

Clomipramine is a tricyclic antidepressant with strong evidence for OCD. It is more effective than SSRIs on average but has more side effects, including dry mouth, sedation, weight gain, and cardiac considerations. It is typically reserved for patients who have not responded to two adequate SSRI trials.

Medication questions?

A psychiatrist experienced in OCD can sequence medication trials properly and interpret partial responses. This is a specialized skill worth searching for.

Find an OCD psychiatrist

Augmentation strategies

For partial responders, augmentation with a low dose atypical antipsychotic such as aripiprazole or risperidone is the most evidence based next step. Roughly a third of SSRI partial responders improve further with augmentation. Other options include memantine, N-acetylcysteine, and combining an SSRI with clomipramine under close cardiac monitoring.

When to consider stopping

Most guidelines recommend continuing effective OCD medication for at least 1 to 2 years after remission. Discontinuation, when appropriate, should be slow, over 3 to 6 months, and paired with ongoing ERP support. Relapse rates on discontinuation are meaningful, so the decision is worth thinking through carefully.

Medications in children and adolescents

SSRIs are used in children and adolescents with OCD and are FDA approved for pediatric OCD in this age group. Sertraline is approved starting at age 6, fluoxetine at age 7, and fluvoxamine at age 8. Pediatric dosing starts low and titrates up slowly over 8 to 12 weeks. The combination of SSRI plus family based CBT with ERP outperforms either alone in pediatric OCD and is the standard first line approach for moderate to severe cases.

Suicide risk warnings on SSRIs apply to children and adolescents and require close monitoring during the first several weeks of treatment and after any dose change. This does not mean SSRIs should be avoided. Untreated moderate to severe OCD carries its own suicide risk, and the balance generally favors treatment with monitoring rather than no treatment.

Medications during pregnancy and while breastfeeding

Sertraline has the strongest safety data in pregnancy and lactation and is often the SSRI of choice when medication is needed. Fluoxetine has a longer track record but higher levels in breast milk. Paroxetine is generally avoided in pregnancy due to a small increase in cardiac malformations. The decision to continue or start medication during pregnancy is a shared one between the patient, the obstetrician, and the psychiatrist, and factors in the severity of the untreated OCD. Our guide to OCD during pregnancy and postpartum covers this in detail.

Drug interactions to watch for

Fluvoxamine and fluoxetine are strong CYP450 inhibitors and interact with many common medications, including some cardiac medications, benzodiazepines, and theophylline. Clomipramine requires baseline and periodic ECG monitoring due to cardiac effects and should not be combined with MAOIs. SSRIs combined with triptans, MAOIs, or high dose tramadol raise the risk of serotonin syndrome. A pharmacist review of the full medication list at the start of any new prescription is worth the time.

When medication does not work

Roughly a third of patients do not achieve meaningful response to SSRIs plus augmentation. For this group, options include intensive residential ERP, transcranial magnetic stimulation which is FDA cleared for OCD, and in severe treatment resistant cases deep brain stimulation which is available at a small number of academic centers. A treatment resistant OCD workup at a specialty center is worth pursuing before concluding that no medication will help. Our guide to residential OCD treatment for adults covers what a residential specialty program can add when outpatient medication management has plateaued.